0001628280-23-033914.txt : 20231004 0001628280-23-033914.hdr.sgml : 20231004 20231004214024 ACCESSION NUMBER: 0001628280-23-033914 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231002 FILED AS OF DATE: 20231004 DATE AS OF CHANGE: 20231004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McAvoy David R. CENTRAL INDEX KEY: 0001758842 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21088 FILM NUMBER: 231309713 MAIL ADDRESS: STREET 1: C/O ENDOCYTE, INC., 3000 KENT AVENUE STREET 2: SUITE A1-100 CITY: WEST LAFAYETTE STATE: IN ZIP: 47906 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fresh Tracks Therapeutics, Inc. CENTRAL INDEX KEY: 0000819050 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 930948554 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (720) 505-4755 MAIL ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: Brickell Biotech, Inc. DATE OF NAME CHANGE: 20190830 FORMER COMPANY: FORMER CONFORMED NAME: VICAL INC DATE OF NAME CHANGE: 19940211 4 1 wk-form4_1696470013.xml FORM 4 X0508 4 2023-10-02 1 0000819050 Fresh Tracks Therapeutics, Inc. FRTX 0001758842 McAvoy David R. C/O FRESH TRACKS THERAPEUTICS, INC. 2000 CENTRAL AVENUE, SUITE 100 BOULDER CO 80301 0 1 0 0 Gen Counsel, CCO, & Secretary 0 Common Stock 2023-10-02 4 M 0 20000 A 23419 D Common Stock 2023-10-02 4 F 0 7358 0.9798 D 16061 D Common Stock 310 I By spouse Restricted Stock Units 2023-10-02 4 M 0 20000 0 D Common Stock 20000 0 D The restricted stock units were granted on January 24, 2023 and were subject to accelerated vesting as of the date of the reporting person's termination pursuant to his employment agreement with the issuer. Each restricted stock unit converted into common stock on a one-for-one basis. This balance includes 555 shares purchased under the Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan that were not previously reported. On July 5, 2022, the registrant effected a 1-for-45 reverse stock split ("Reverse Stock Split") of its common stock. The number of shares beneficially owned has been adjusted to give effect to the Reverse Stock Split. Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. The restricted stock units vested in full on October 2, 2023. /s/ Christine G. Long, Attorney-in-Fact for David R. McAvoy (power of attorney previously filed) 2023-10-04